Mills Frederic Baker, Misra Anuruddh K, Goyeneche Nicholas, Hackel Joshua G, Andrews James R, Joyner Patrick W
University of South Carolina School of Medicine, Columbia, South Carolina, USA.
Premise Health, San Francisco, California, USA.
Orthop J Sports Med. 2021 Mar 17;9(3):2325967121991135. doi: 10.1177/2325967121991135. eCollection 2021 Mar.
Ulnar collateral ligament (UCL) injuries of the elbow are uncommon in the general population but prevalent in the athletic community, particularly among baseball players. Platelet-rich plasma (PRP) injection therapy has become a popular nonoperative adjuvant treatment for such injuries to help reduce recovery time and avoid surgery.
PURPOSE/HYPOTHESIS: To analyze patient outcomes by injury severity and identify injury types that responded most favorably and unfavorably to PRP treatment. It was hypothesized that PRP therapy would prove to be most beneficial in the treatment of lower-grade, partial UCL tears and less effective in the treatment of more severe, complete UCL tears.
Cohort study; Level of evidence, 3.
A cohort of 50 patients with UCL injuries in their dominant elbow, diagnosed by MRI (magnetic resonance imaging) arthrogram, underwent PRP therapy in conjunction with an established rehabilitation program. UCL injuries were classified by MRI as low-grade partial tear (Type I), high-grade partial tear (Type II), complete tear (Type III), or tear in more than 1 location (Type IV).
In total, 24 of 39 (61.5%) Type I and II tears, 3 of 3 (100%) Type III tears, and 1 of 8 (12.5%) patients with Type IV tears responded to UCL PRP injection therapy and were able to return to play without surgery. Ten patients required subsequent UCL PRP injections, of which 3 (30%) were able to return to sport without surgery.
PRP treatment for Types I and II UCL tears shows great promise when combined with physical therapy and a rehabilitation program. Type III UCL tears demonstrated a high rate of success, although with low cohort numbers. Type IV UCL tears did not appear to respond well to PRP injection therapy and often required surgical intervention or cessation of sport. Therefore, PRP treatment does not appear to be appropriate for patients with complete Type IV UCL tears but may enhance recovery and improve outcomes in throwing athletes with Types I, II, and III UCL injuries.
尺侧副韧带(UCL)损伤在普通人群中并不常见,但在运动员群体中较为普遍,尤其是在棒球运动员中。富血小板血浆(PRP)注射疗法已成为此类损伤常用的非手术辅助治疗方法,有助于缩短恢复时间并避免手术。
目的/假设:按损伤严重程度分析患者预后,并确定对PRP治疗反应最有利和最不利的损伤类型。假设PRP疗法在治疗较低级别的部分UCL撕裂时效果最佳,而在治疗较严重的完全UCL撕裂时效果较差。
队列研究;证据等级,3级。
通过磁共振成像(MRI)关节造影诊断为优势侧肘部UCL损伤的50例患者组成队列,接受PRP治疗并结合既定的康复计划。UCL损伤经MRI分类为低级部分撕裂(I型)、高级部分撕裂(II型)、完全撕裂(III型)或多处撕裂(IV型)。
总计,39例I型和II型撕裂中有24例(61.5%)、3例III型撕裂中有3例(100%)以及8例IV型撕裂中有1例(12.5%)对UCL PRP注射疗法有反应,能够在不进行手术的情况下恢复比赛。10例患者需要后续的UCL PRP注射,其中3例(30%)能够在不进行手术的情况下恢复运动。
I型和II型UCL撕裂采用PRP治疗并结合物理治疗和康复计划时显示出巨大前景。III型UCL撕裂成功率较高,尽管队列数量较少。IV型UCL撕裂似乎对PRP注射疗法反应不佳,通常需要手术干预或停止运动。因此,PRP治疗似乎不适用于完全IV型UCL撕裂的患者,但可能会促进I型、II型和III型UCL损伤的投掷运动员的恢复并改善预后。